The global blood culture tests market size was valued at USD 6.67 billion in 2025 and is projected to grow from USD 7.36 billion in 2026 to USD 16.14 billion by 2034, registering a CAGR of 10.32% during the forecast period from 2026 to 2034. North America dominated the blood culture tests market with a market share of 38.6% in 2025.
Blood culture tests are laboratory tests used to detect microorganisms, such as bacteria or fungi, that may be present in a person’s bloodstream. A healthcare professional collects blood samples and places them into specialized culture bottles that provide suitable conditions for microorganisms to grow. The samples are then monitored in a laboratory, and if growth occurs, further testing can help identify the organism and determine which antimicrobial medicines may be effective. Blood cultures are commonly used when a serious bloodstream infection is suspected, including conditions such as sepsis. Because contamination from microorganisms on the skin can affect results, careful collection and handling of the blood sample are important for obtaining reliable findings.
Download a Free Sample To learn more about this report,
Blood Culture Workflows Are Integrating With Laboratory Information Systems
The need for faster, more accurate handling of time-sensitive blood culture results is increasing the integration of testing workflows with laboratory information systems. This transition connects blood culture orders, specimen details, results, contamination tracking, and reporting within digital laboratory workflows, with the CDC specifically recommending LIS data to calculate blood culture contamination and single-set rates on a monthly basis. The outcome is better result traceability, fewer manual steps, and stronger laboratory quality monitoring.
Contamination Reduction Is Becoming a Major Blood Culture Quality Priority
The blood culture tests market analysis shows that the clinical consequences of false-positive cultures, including unnecessary antibiotic use and prolonged hospitalization, are increasing the focus on contamination prevention during blood culture collection. This transition is encouraging laboratories to monitor contamination rates, standardize collection procedures, and provide feedback to clinical teams, with the CDC noting that an overall contamination rate of 3% or lower is recommended and that rates around 1% are achievable with best practices. The outcome is more reliable blood culture results and reduced diagnostic and treatment errors.
Expansion of Hospital and Intensive Care Facilities and Increasing Incidence of Bloodstream Infections Drive Market
Expansion of hospitals and intensive care facilities increases demand for blood culture tests because larger clinical capacity creates more testing requirements for patients with suspected infections. Intensive care units, for example, regularly evaluate critically ill patients with fever or suspected sepsis using blood cultures to identify bloodstream pathogens. This broader hospital infrastructure supports recurring procurement of blood culture bottles, testing systems, and related laboratory supplies.
A higher incidence of bloodstream infections increases demand for blood culture tests as healthcare providers require laboratory confirmation of pathogens circulating in the blood. Patients with suspected sepsis, for example, may undergo blood culture testing to help identify the causative organism and guide antimicrobial treatment. This larger diagnostic workload increases testing volumes across hospitals and microbiology laboratories, supporting continued demand for blood culture products.
High Cost of Blood Culture Testing and Laboratory Maintenance and Challenges in Detecting Slow-Growing and Difficult-to-Culture Pathogens Restrain Market Expansion
High costs of blood culture testing, automated systems, reagents, equipment, and laboratory maintenance can increase the financial burden on healthcare facilities. Higher operating and maintenance expenses can limit adoption in smaller hospitals and resource-constrained laboratories. Consequently, cost pressures can delay investments and restrict market expansion.
Challenges in detecting slow-growing and difficult-to-culture pathogens can reduce the effectiveness and efficiency of conventional blood culture testing. Longer incubation periods and specialized testing requirements can delay diagnosis and increase the need for additional diagnostic methods. As a result, detection limitations can slow adoption and constrain market growth.
Blood Culture Tests for Antimicrobial Resistance Detection and Blood Culture Tests for Decentralized Diagnostic Settings Offer Growth Opportunities
Hospitals, microbiology laboratories, and infectious disease centers are key customers for blood culture solutions that support rapid identification of antimicrobial-resistant bloodstream infections. Companies such as bioMérieux and BD can expand revenue through advanced culture systems, resistance-focused testing solutions, and specialized laboratory partnerships.
Emergency departments, community hospitals, and decentralized healthcare facilities are key customers for blood culture testing solutions designed for faster and more accessible diagnostic workflows. Companies such as Thermo Fisher Scientific can generate revenue through compact testing systems, consumables, and diagnostic partnerships with healthcare providers, contributing to blood culture tests market growth.
Delayed Turnaround Time and Workflow Bottlenecks and Blood Culture Contamination and False-Positive Results Hinder Growth
Blood culture testing requires incubation and multiple laboratory steps before pathogens can be identified and susceptibility results become available. Longer turnaround times can delay clinical decision-making and increase workflow pressure on laboratories, making it harder for healthcare providers to scale conventional blood culture testing efficiently.
Blood culture contamination during specimen collection or handling can produce false-positive results that trigger additional testing, unnecessary antibiotic use, and increased hospital resource utilization. Higher contamination rates can reduce confidence in testing workflows and require laboratories to invest in improved collection practices and quality control, creating additional operational challenges for market expansion.
The automated blood culture methods segment accounted for a market share of 63.2% in 2025 due to their ability to provide continuous monitoring, automated detection, and faster identification of microbial growth compared with manual testing approaches. Integration of automated systems into clinical laboratories supports efficient blood culture processing and contributes to the segment’s dominant market position.
The conventional blood culture methods segment is expected to grow at a CAGR of 7.82% during the forecast period 2026-2034, driven by their established use for detecting bloodstream infections through manual incubation, observation, and laboratory analysis. Their accessibility and suitability for laboratories with conventional testing infrastructure support continued adoption of these methods.
Request Customizationto receive a tailored report.
The software and services segment is expected to grow at a CAGR of 10.76% during the forecast period 2026-2034, driven by the integration of laboratory software, data management, maintenance, and technical support services with blood culture testing systems. Digital workflow management and automated data analysis support efficient laboratory operations and create demand for software and service solutions.
The consumables segment accounted for a market share of 61.5% in 2025 due to the recurring use of culture bottles, reagents, media, and other disposable components required for blood culture testing. Continuous testing volumes and the need for replacement consumables across clinical laboratories support the segment’s dominant market position. The instruments segment includes automated blood culture analyzers and related laboratory equipment used to detect and monitor microbial growth in blood samples. Demand for efficient laboratory testing, faster detection, and integration with automated diagnostic workflows supports continued adoption of blood culture instruments.
The bacterial segment accounted for a market share of 72.6% in 2025 due to the frequent use of blood culture testing for detecting bloodstream infections caused by bacterial pathogens. The need for timely identification of bacterial infections supports its dominant position in blood culture testing applications.
The fungal segment is expected to grow at a CAGR of 10.02% during the forecast period 2026-2034, driven by the use of blood culture testing to detect invasive fungal infections, particularly in patients with compromised immune systems. Improved diagnostic capabilities and the need for timely identification of fungal pathogens support demand for fungal blood culture testing.
Speak to an Analystto discuss market opportunities.
The North America blood culture tests market accounted for the largest regional share of 38.6% in 2025, supported by the high burden of bloodstream infections and sepsis, with the CDC reporting that about 1.7 million U.S. adults develop sepsis each year and at least 350,000 die during hospitalization or are discharged to hospice, while blood cultures remain an important diagnostic test for identifying infection-causing pathogens.
The US blood culture tests market will be supported by continued demand for sepsis diagnosis, with the 2026 Surviving Sepsis Campaign recommending that blood cultures be collected as soon as possible and ideally before antimicrobial therapy, while U.S. sepsis burden remains substantial, supporting continued use of blood-culture diagnostics. Canada blood culture tests market will be supported by continued focus on bloodstream-infection surveillance and rapid pathogen detection, with Canada targeting a reduction in MRSA bloodstream infections to at most 0.7 cases per 1,000 hospital admissions by 2026, while the Public Health Agency of Canada plans to maintain laboratory capacity to accurately test for 99-100% of pathogens of national and international concern through 2026-27, supporting demand for blood-culture and related diagnostic testing.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe blood culture tests market is expected to grow at a CAGR of 10.48% during the forecast period 2026–2034, supported by continued antimicrobial-resistance surveillance and bloodstream-infection prevention, with the EU targeting a 15% reduction in MRSA bloodstream infections, a 10% reduction in third-generation cephalosporin-resistant E. coli bloodstream infections, and a 5% reduction in carbapenem-resistant K. pneumoniae bloodstream infections by 2030, increasing the need for pathogen identification and susceptibility testing.
UK blood culture tests market: The UK blood culture tests market will be supported by antimicrobial-resistance control, with the UK targeting no increase in Gram-negative bloodstream infections by 2029 and 70% of human antibiotic use from the Access category by 2029, supporting continued demand for bloodstream-infection diagnostics.
Germany blood culture tests market: The Germany blood culture tests market will be supported by antimicrobial-resistance surveillance, with DART 2030 targeting by 2030 a 10% reduction in MRSA bloodstream infections, a 12% reduction in third-generation-cephalosporin-resistant E. coli bloodstream infections, and a 2% reduction in carbapenem-resistant K. pneumoniae bloodstream infections, strengthening demand for pathogen identification and susceptibility testing. France blood culture tests market: The France blood culture tests market will be supported by diagnostic innovation, with France’s 2025-2034 implementation of its AMR roadmap focusing on the development of new preventive, diagnostic, and therapeutic products and their progression toward industrialization, supporting demand for microbiological and bloodstream-infection diagnostics.
The Asia Pacific blood culture tests market accounted for a regional share of 22.7% in 2025, supported by the region’s high antimicrobial-resistance burden, with WHO’s 2025-2030 South-East Asia roadmap targeting stronger AMR surveillance and laboratory capacity by 2030, while WHO identifies South-East Asia as one of the regions where antibiotic resistance is highest, increasing the need for bloodstream-infection diagnostics and pathogen identification.
China blood culture tests market will be supported by antimicrobial-resistance diagnostics, with China’s national AMR action plan targeting the development of 5-10 new microbial diagnostic instruments and reagents and continued expansion of antimicrobial-use and resistance surveillance networks, strengthening demand for pathogen identification and blood culture testing. Japan blood culture tests market will be supported by strengthened AMR surveillance and laboratory capacity, with Japan’s National AMR Action Plan running through 2027 and setting numerical outcome targets across surveillance, infection prevention, antimicrobial stewardship, and research and development, supporting continued demand for microbiological diagnostic testing.
South Korea blood culture tests market will be supported by stronger antimicrobial-resistance diagnostics, with the country’s Third National Action Plan on AMR covering 2026-2030 and prioritizing expanded AMR surveillance, infection prevention, antimicrobial stewardship, and development of diagnostic technologies, increasing demand for pathogen identification and susceptibility testing. India blood culture tests market will be supported by laboratory-capacity expansion, with India’s National Action Plan on Antimicrobial Resistance 2025-2029 prioritizing enhanced laboratory capacity and infection control in healthcare facilities, while its implementation framework includes 14 key performance indicators for monitoring and evaluation, supporting demand for microbiological and bloodstream-infection diagnostics.
The blood culture tests market is moderately concentrated, with major in-vitro diagnostics companies, clinical microbiology specialists, laboratory automation providers, molecular diagnostics companies, and regional diagnostic suppliers competing across automated blood culture systems, culture media, instruments, and rapid identification technologies. Leading players such as Becton Dickinson and Company, bioMérieux SA, Thermo Fisher Scientific Inc., Bruker Corporation, and F. Hoffmann-La Roche Ltd. collectively account for approximately 60% of the global blood culture tests market share in 2025.
Established players compete primarily on detection accuracy, time to detection, microbial recovery, automation, installed laboratory base, and global distribution, while emerging players in the blood culture tests market ecosystem compete through rapid pathogen identification, decentralized testing, specialized assays, flexible integration, and lower workflow complexity. The competitive landscape is also shaped by the convergence of microbiology and molecular diagnostics, with established companies such as BD, bioMérieux, and Thermo Fisher offering automated blood culture systems while newer technology providers focus on faster identification and antimicrobial-resistance detection.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Cell Line Development Services Market Size, Share, 2034
Base Editing Market Size, Share, Growth, Analysis, Report, 2034
Metagenomic Sequencing Market Size, Share, Growth, Analysis, 2034
Gene Therapy Cell Culture Media Market Size, Share, Growth, 2034
CRISPR-Cas9 Gene Editing Technologies Market Size, Share, 2034
Immunoprotein Diagnostic Testing Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com